Dr. Lonial on Treating Early Relapse in Multiple Myeloma

Video

In Partnership With:

Sagar Lonial, MD, FACP, discusses the management of patients with relapsed multiple myeloma.

Sagar Lonial, MD, FACP, professor and chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the management of patients with relapsed multiple myeloma.

Patients with early relapse will progress on one prior line of therapy, says Lonial. However, patient outcomes in this space have improved dramatically over the past 10 years.

Notably, some patients with early relapse may experience a remission duration that is as long as their original remission, explains Lonial. This is due, in part, to the availability of agents such as daratumumab (Darzalex), carfilzomib (Kyprolis), and pomalidomide (Pomalyst).

Related Videos
Vishal Patel, MD, FAAD, FACMS, associate professor, Dermatology, George Washington (GW) School of Medicine & Health Sciences
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP